Bristol-Myers Squibb and Pharmasset to investigate hepatitis therapy

[Guest guest]

http://www.zenopa.com/news/800334314/Bristol_Myers_Squibb_and_Pharmasset_to_inve\

stigate_hepatitis_therapy

Bristol-Myers Squibb and Pharmasset to investigate hepatitis therapy

Posted on 11/01/2011 in Pharmaceutical Company Product News

Bristol-Myers Squibb is to collaborate with fellow pharmaceutical company

Pharmasset to investigate a potentially promising new means of treating

hepatitis C.

The companies will conduct a proof of concept study that will evaluate the

potential efficacy of the NS5A replication complex inhibitor BMS-790052 among

chronic hepatitis C patients when used in combination with Pharmasset's

nucleotide polymerase inhibitor PSI-7977.

This research will aim to achieve sustained viral response 24 weeks after

treatment via a once-daily regimen and represents the first cross-company

collaboration to combine two oral agents to combat hepatitis C.

Bristol-Myers Squibb and Pharmasset will begin the study during the first half

of 2011.

s, senior vice-president for development at Bristol-Myers Squibb,

said: " Conducting this study highlights Bristol-Myers Squibb's ability to

collaborate with other companies to develop innovative combination therapies in

areas of high unmet need. "

[Guest guest]

http://www.zenopa.com/news/800334314/Bristol_Myers_Squibb_and_Pharmasset_to_inve\

stigate_hepatitis_therapy

Bristol-Myers Squibb and Pharmasset to investigate hepatitis therapy

Posted on 11/01/2011 in Pharmaceutical Company Product News

Bristol-Myers Squibb is to collaborate with fellow pharmaceutical company

Pharmasset to investigate a potentially promising new means of treating

hepatitis C.

The companies will conduct a proof of concept study that will evaluate the

potential efficacy of the NS5A replication complex inhibitor BMS-790052 among

chronic hepatitis C patients when used in combination with Pharmasset's

nucleotide polymerase inhibitor PSI-7977.

This research will aim to achieve sustained viral response 24 weeks after

treatment via a once-daily regimen and represents the first cross-company

collaboration to combine two oral agents to combat hepatitis C.

Bristol-Myers Squibb and Pharmasset will begin the study during the first half

of 2011.

s, senior vice-president for development at Bristol-Myers Squibb,

said: " Conducting this study highlights Bristol-Myers Squibb's ability to

collaborate with other companies to develop innovative combination therapies in

areas of high unmet need. "